We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Expanded Sequencing Panel Supports Myeloid Malignancy Variant Profiling

By LabMedica International staff writers
Posted on 07 Oct 2026

Myeloid malignancies require molecular profiling to detect variants relevant to disease characterization and research. More...

FLT3 internal tandem duplications occur in an estimated 20–30% of de novo acute myeloid leukemia cases and are associated with poor prognosis, but longer repetitive insertions can be difficult for short-read sequencing assays to size accurately. Now, a newly launched research-use-only panel expands myeloid gene coverage while improving detection of long and multiple FLT3 internal tandem duplications.

Pillar Biosciences (Natick, MA, USA) has launched the oncoReveal Myeloid v2 Panel, an expanded research-use-only (RUO) DNA next-generation sequencing (NGS) panel for myeloid malignancies. The panel expands the original oncoReveal Myeloid Panel from 58 to 80 gene targets. It adds 22 genes while retaining all prior content, giving laboratories broader guideline-relevant coverage without disrupting existing workflows.

The new version uses Pillar’s proprietary SLIMamp chemistry and VersaTile primer design tool to support panel scaling. Only four of the original 766 amplicons covering the original 58 genes were changed to accommodate the expanded content. The panel is also paired with PiVAT informatics to support detection and sizing of FLT3 internal tandem duplications using standard 2 x 150 bp short-read sequencing.

In an independent evaluation of 111 samples, including 23 FLT3-ITD-positive samples with internal tandem duplications ranging from 12 bp to 279 bp, the panel and PiVAT informatics accurately detected and sized these variants. The evaluation included internal tandem duplications up to 279 bp and nine samples with two to four concurrent internal tandem duplications. FLT3 internal tandem duplications were detected to 1% or lower variant allele frequency. NGS-derived variant allele frequencies trended consistently with allelic ratios from orthogonal capillary electrophoresis-based fragment analysis across the evaluated internal tandem duplication lengths.

Detection of long and multiple internal tandem duplications in a single NGS run can identify distinct clonal populations within the same sample. Each population may have its own internal tandem duplication length and variant allele frequency. This level of detail can be obscured by a single capillary electrophoresis-based allelic ratio.

“With oncoReveal Myeloid v2, we significantly expanded our myeloid gene content while preserving the trusted panel content laboratories already rely on. We also invested significant effort in FLT3-ITD detection so laboratories can obtain accurate, base-pair-resolved calls for long and multiple ITDs without defaulting to a separate fragment-analysis workflow,” said ShiPing Zou, Senior Director, Product Management at Pillar Biosciences.

Related Links
Pillar Biosciences

 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.